myirislogo
18 June, 2018 07:45 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Power Grid 198.50 0.25
Sun Pharma 571.05 2.04
Tcs 1841.45 2.75
State Bank O 277.55 1.82
Tata Stl 565.95 0.61
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Cipla Limited
Cipla Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:500087NSE:CIPLABloomberg:CIPLA@INReuters:CIPL.BO
Market Lot: 1Face Value: 2ISIN Demat: INE059A01026
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
14-JUN-18 Cipla, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Isoproterenol Hydrochloride Injection USP, 0.2mg/mL, single-use sterile Ampoule from the United States Food and Drug Administration (US FDA). 08-JUN-18 Unitaid and Indian drug manufacturer Cipla struck a landmark agreement today that will lower the price of the first combination therapy (containing co-trimoxazole, isoniazid and vi...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Cipla, Unitaid enter into landmark deal to lower price of HIV drug  -IRIS 08-Jun-18
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Dec-2017(9)31-Mar-2017(12)31-Mar-2016(12)
Net sales 85510.50107505.10117351.80
Other Income2720.001392.102591.40
Total Income88230.50108897.20119943.20
Cost of goods sold69551.0097314.9099803.40
OPBDIT18679.5011582.3020139.80
PAT12437.109750.8013980.30
Gross Block---
Equity capital--1606.80
EPS (Rs.)---
DPS (Rs.)---
BV (Rs.)---
P/E range (x)---
Debt / Equity (x)---
Operating margin (% of OI)21.210.616.8
Net margin (% of OI)14.1 9.011.7
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Mumbai Central
Mumbai
Maharashtra-400 008
PHONE
(022) 2309 5521 / 2302 5272
FAX
(022) 2300 8101
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer